{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:55:24Z","timestamp":1788479724052,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["64165"],"award-info":[{"award-number":["64165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016366","name":"V\u0161eobecn\u00e1 Fakultn\u00ed Nemocnice v Praze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jctejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical & Translational Endocrinology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcte.2025.100418","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:30:30Z","timestamp":1756402230000},"page":"100418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0001-9935","authenticated-orcid":false,"given":"H\u00e1na","family":"V\u00e1clav Jr.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van\u011b\u010dkov\u00e1","family":"Manuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kr\u0161ek","family":"Michal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krausov\u00e1","family":"Ad\u00e9la","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je\u017ekov\u00e1","family":"Jana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kos\u00e1k","family":"Mikul\u00e1\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibl\u00edk","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netuka","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masopust","family":"V\u00e1clav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1jovsk\u00fd","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u0161\u010d\u00e1k","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e1na","family":"V\u00e1clav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcte.2025.100418_b0005","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1530\/EJE-14-0013","article-title":"Therapy of endocrine disease: the challenges in managing giant prolactinomas","volume":"170","author":"Maiter","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.jcte.2025.100418_b0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1530\/EJE-06-0646","article-title":"Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men","volume":"156","author":"Shimon","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.jcte.2025.100418_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jcte.2025.100418_b0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1210\/js.2017-00038","article-title":"Cabergoline tapering is almost always successful in patients with macroprolactinomas","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc"},{"issue":"3","key":"10.1016\/j.jcte.2025.100418_b0025","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12020-015-0791-7","article-title":"Giant prolactinomas: are they really different from ordinary macroprolactinomas?","volume":"52","author":"Espinosa","year":"2016","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.jcte.2025.100418_b0030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4158\/EP-2018-0392","article-title":"Management and outcomes of giant prolactinoma: a series of 71 patients","volume":"25","author":"Hamidi O ksana","year":"2019","journal-title":"Endocr Pract"},{"issue":"12","key":"10.1016\/j.jcte.2025.100418_b0035","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1210\/clinem\/dgad393","article-title":"Long-term follow-up of 84 patients with giant prolactinomas-a swedish nationwide study","volume":"108","author":"Himonakos","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.jcte.2025.100418_b0040","article-title":"Dopamine agonists for idiopathic hyperprolactinaemia and prolactinoma in adults","volume":"2018","author":"Nunes-Nogueira","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.jcte.2025.100418_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.jcte.2025.100418_b0050","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa1307557","article-title":"Mutant prolactin receptor and familial hyperprolactinemia","volume":"369","author":"Newey","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcte.2025.100418_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2023.967407","article-title":"Prolactinomas in adolescent and elderly patients\u2014A comparative long-term analysis","volume":"10","author":"Andereggen","year":"2023","journal-title":"Front Surg"},{"key":"10.1016\/j.jcte.2025.100418_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220971","article-title":"Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective","author":"Mohan","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jcte.2025.100418_b0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/eje.0.1490017","article-title":"Development of acromegaly in patients with prolactinomas","volume":"149","author":"Andersen","year":"2003","journal-title":"Eur J Endocrinol"}],"container-title":["Journal of Clinical & Translational Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623725000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623725000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:15:22Z","timestamp":1778523322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214623725000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":13,"alternative-id":["S2214623725000365"],"URL":"https:\/\/doi.org\/10.1016\/j.jcte.2025.100418","relation":{},"ISSN":["2214-6237"],"issn-type":[{"value":"2214-6237","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical & Translational Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcte.2025.100418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100418"}}